Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

MDMA chair: Delcath Systems' CEO Eamonn Hobbs took over the Medical Device Manufacturers Association board of directors as chairman May 25 during the group's annual meeting in Washington, D.C. He replaces outgoing chair Joe Kiani, CEO of Masimo. Hobbs joined Delcath, which develops novel delivery systems for cancer drugs, last July. He co-founded interventional radiology and oncology firm AngioDynamics in 1988 and served as its president and CEO until early 2009 (1"The Gray Sheet" July 20, 2009)

You may also be interested in...



People In Brief

The latest moves by movers and shakers in the medical device and diagnostics industries

People In Brief

Interventional pulmonology CEO: Emphysema device developer Pulmonx announced the hiring of Michael A. Baker as president and CEO July 15. Baker resigned from his 11-year post as CEO of ArthroCare in February in the shadow of an accounting scandal and government investigations (1"The Gray Sheet" Feb. 23, 2009). He also previously served as an executive for Medtronic. The Pulmonx announcement comes two months after the start-up acquired failed endobronchial valve-maker Emphasys Medical and several weeks following 510(k) clearance of its Chartis collateral ventilation detection system, which can be used to identify candidates best suited for lung volume reduction procedures using the Emphasys EBV valve (2"The Gray Sheet" May 18, 2009). Former CEO Ronald Steckel left the firm in November 2008

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

Topics

UsernamePublicRestriction

Register

MT028947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel